This Schedule 14D-9 relates to the tender offer by Dodgers Merger Sub, Inc., a Delaware corporation Subject Company Information Name and Address above. The name, business address and business telephone number of the Company are set forth in The filing person is the subject company. As of the close of business on August 31, 2017, there were 57,410,242 Shares issued and outstanding. The title of the class of equity securities to which this Schedule 14D-9 relates is the CompanysĬommon stock, par value $0.001 per share (the Shares and each, a Share). The Companys telephone number at such address The Companys principal executive offices are located at 2225 Colorado Avenue, Santa Monica, California 90404. Company), a corporation organized under the laws of Delaware. Schedule 14D-9 (together with any exhibits and annexes attached hereto, this Schedule 14D-9) relates is Kite Pharma, Inc. The name of the subject company to which this Solicitation/Recommendation Statement on PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS. INTEREST IN SECURITIES OF THE SUBJECT COMPANY.
PERSON/ASSETS, RETAINED, EMPLOYED, COMPENSATED OR USED. PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS. IDENTITY AND BACKGROUND OF FILING PERSON. On behalf of the persons filing statement)Ĭheck the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. (Name, address and telephone numbers of person authorized to receive notices and communications
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
0 kommentar(er)
